PDCD1 and posterior cortical atrophy: More so, the ectopic expression of AIM significantly enhances the anticancer effect of the anti-PD1 therapeutic antibody, Pembrolizumab, and elicits an increased CD8+ T-cell count in AIMhiPSAloPDL1+ PCa cases that are respondent to Pembrolizumab treatment.